Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor

Doğan, Canan Sercan; Birdir, Cahid; Callies, R.; Kühn, Ulrich; Gellhaus, Alexandra; Janetzko, Alfred; Kasimir‐Bauer, Sabine

doi:10.1515/cclm.2007.316

Cited by 8 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8][9] Reduced PlGF levels have been suggested to be a result of inadequate placental production, 12 which has been previously reported. 7,32 Qazi et al 33 have examined the circulating levels of VEGF and sFlt-1 and suggested that decreased VEGF levels resulting from elevated sFlt-1 might be a potential cause of the pathogenesis of preeclampsia.…”

Section: Discussionmentioning

confidence: 99%

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

et al. 2010

View full text Add to dashboard Cite

This study was designed to test the hypothesis that altered angiogenic factors together with increased oxidative stress and reduced docosahexaenoic acid (DHA) levels may be associated with altered birth outcome parameters. To test this hypothesis, levels of plasma vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), the oxidative stress marker malondialdehyde (MDA) and fatty acids were estimated in women with preeclampsia and their cord samples and compared with those in normotensive women. The association of these parameters with birth outcome was also examined. Our results show that in preeclamptic women, maternal plasma VEGF and PlGF levels were lower, whereas sFlt-1 levels were higher (Po0.05 for all) than in normotensive women. In contrast, cord plasma VEGF levels were higher (Po0.05) in preeclamptic women, whereas there was no difference in sFlt-1 levels. Plasma DHA levels in both the mother and cord were lower (Po0.05) in the preeclamptic group compared with normotensive women. Maternal plasma sFlt-1 levels were positively (n¼23, r¼0.415, P¼0.039) associated with MDA concentrations in preeclamptic women. Maternal plasma sFlt-1 levels showed a strong negative association with baby weight (n¼37, r¼À0.547, P¼0.001), head circumference (n¼37, r¼À0.472, P¼0.005) and baby chest circumference (n¼37, r¼À0.375, P¼0.032) in the preeclamptic group. Cord plasma sFlt-1 concentrations were negatively associated with cord plasma DHA concentrations (n¼28, r¼À0.552, P¼0.004). This study suggests that dysregulation of angiogenic factors may be associated with maternal oxidative stress. Increased oxidative stress may reduce cord DHA levels and increase sFlt-1 levels, leading to poor birth outcomes in preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…We have recently demonstrated that the PLGF concentrations in normal pregnancies show a steady increase starting at 15 weeks of pregnancy with a peak at 28-32 weeks and a consistent decline thereafter. PLGF serum levels of patients with preeclampsia are significantly lower than the levels in nonpreeclamptic pregnancies [16] . At present, the women at risk of preeclampsia are identified on the basis of epidemiological, clinical and anamnestic risk factors.…”

Section: Introductionmentioning

confidence: 68%

“…From the beginning of the second trimester at 15 weeks of pregnancy, PLGF concentrations showed a steady increase until 30-32 weeks [16] . Our study depicts the expression of PLGF between 15 and 18 weeks of pregnancy in patients joining our clinic for invasive prenatal diagnostics.…”

Section: Commentmentioning

confidence: 98%

“…An imbalance between the factors promoting angiogenesis such as vascular endothelial growth factor or PLGF and factors antagonizing angiogenesis such as sFLT1 plays a fundamental role in the pathogenesis of preeclampsia [15,16] . Decreased concentrations of circulating free PLGF and free vascular endothelial growth factor have been noted during clinical preeclampsia [20][21][22][23] .…”

Section: Commentmentioning

confidence: 99%

“…An imbalance of angiogenic and growth factors at the maternal-fetal interface and a consecutive imbalance of these factors in maternal blood might lead to the clinical symptoms hypertension and proteinuria [11][12][13][14] . An imbalance between the factors promoting angiogenesis such as vascular endothelial growth factor or placental growth factor (PLGF) and the factors antagonizing angiogenesis such as soluble fms-like tyrosine kinase 1 (sFLT1) plays a fundamental role in the pathogenesis of preeclampsia [15,16] . We have recently demonstrated that the PLGF concentrations in normal pregnancies show a steady increase starting at 15 weeks of pregnancy with a peak at 28-32 weeks and a consistent decline thereafter.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Placental Growth Factor: A Predictive Marker for Preeclampsia?

Doğan¹,

Birdir²,

Kühn³

et al. 2009

Gynäkol Geburtshilfliche Rundsch

Self Cite

View full text Add to dashboard Cite

Background: An imbalance between angiogenic and antiangiogenic factors plays a fundamental role in the pathogenesis of preeclampsia. Serum levels of placental growth factor (PLGF), a factor promoting angiogenesis, in patients with preeclampsia are significantly lower than in nonpreeclamptic pregnancies. This study was designed to answer the question whether the measurement of PLGF at the beginning of the second trimester might be a predictive factor for the appearance of preeclampsia. Methods: Serum samples of 61 women were collected between 15 and 18 weeks of pregnancy. PLGF levels were measured using a human PLGF ELISA and correlated with the outcomes of pregnancy. Results: 7 women (11.47%) developed preeclampsia during pregnancy. Their PLGF levels between 15 and 18 weeks of pregnancy were significantly lower (p < 0.001) compared to the nonpreeclamptic pregnancies. Using a PLGF level of 41.84 pg/ml as a cutoff, this test has a sensitivity of 0.87 and a specificity of 0.83. Conclusion: Women who will develop preeclampsia in the course of pregnancy already have a significantly lower expression of PLGF between 15 and 18 weeks of pregnancy compared to those who will not. This test offers new possibilities in the prediction of preeclampsia.

show abstract

Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening

et al. 2009

View full text Add to dashboard Cite

show abstract

Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor

Cited by 8 publications

References 38 publications

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

Placental Growth Factor: A Predictive Marker for Preeclampsia?

Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening

Contact Info

Product

Resources

About